Revolutionizing Bladder Cancer with Dendritic Cell Treatment

While some other immunotherapies use Dendritic Cells, Immunocine’s method is entirely different in how we use them.

Others have focused on what to add to these cells — tumor fragments, RNA, bacteria, toxins — hoping something triggers a response. But we discovered it’s not just about what you give them, but how you give it. Our proprietary Double Loading technique introduces the cancer’s full message in a way that activates Dendritic Cells the way nature intended.

Think of it like having the right key — it’s useless unless you insert it into the lock the right way. Our method flips both immune activation “switches,” leading to results that go far beyond traditional approaches. It’s not a marginal improvement — it’s a qualitative leap.

We also time our cell administration based on immune kinetics, deliver them where the immune system operates best, and combine it all with scientific precision and compassionate care. No one else is doing all of this — together.

Our technology doesn’t target a single cancer type — it targets the immune system’s failure to recognize cancer at all.

Dendritic Cells, when trained correctly, can identify and mobilize against any abnormal cell. Whether your cancer started in the breast, prostate, pancreas, or elsewhere, the immune system doesn’t care about labels — it cares about threats.

We’ve seen success across a wide range of cancers and mutations. And because we’re working with the full picture — not one marker or receptor — our results aren’t limited by subtype. The immune system is designed to protect the entire body. We just help it remember how.

Our approach has been published in multiple peer-reviewed journals, particularly highlighting our Double Loading method and the underlying immune activation mechanisms. These papers explain the cellular processes in detail and have passed rigorous scientific scrutiny. Why is that important? Because it means our work isn’t theoretical or proprietary guesswork. It’s transparent, reproducible, and backed by expert review — the gold standard in science.

Unlike some clinics that cite generic immunotherapy research, we only reference studies directly tied to our specific method. You can view these on our Research page.

That’s a common — and often misleading — statement. Most doctors who say this are referring to a narrow slice of immunotherapy, like checkpoint inhibitors (e.g., Keytruda, Opdivo), which only work if certain markers like PD-L1 are present. But immunotherapy is a broad category, and our approach is entirely different.

Checkpoint inhibitors remove immune system “brakes.” We re-educate your immune system from scratch — using your own cancer to teach it what to attack. It’s not a passive hope that your immune system will notice the cancer. It’s an active lesson plan, using your cancer as the textbook.

We also:
• Use your entire tumor’s mRNA and protein library — not just one target.
• Deliver immune instructions using our unique Double Loading technique.
• Time and direct the delivery based on immune kinetics and trafficking rules.
• Work regardless of PD-L1 status or prior treatments.

Your immune system likely isn’t broken — it’s just never been properly introduced to the problem. That’s our specialty.

Yes — and it’s one of the most exciting findings from our patients.

Following our treatment, some patients have shown changes in their cancer’s PD-L1 expression, potentially creating new therapeutic opportunities. Why? Because their immune system is finally fighting back, and the cancer is mounting a defense.

This immune activity causes the cancer to “throw up shields” — like PD-L1 — which weren’t needed before because it wasn’t under attack. That’s when checkpoint inhibitors may suddenly become effective.

We’re not just treating cancer — we’re changing how your immune system sees it, which can unlock future therapies.

Most side effects are mild and stem from immune activation — a sign that your body is finally recognizing and responding to the cancer. These may include:

• Fatigue (most common)
• Flu-like symptoms
• Muscle aches
• Swollen lymph nodes
• Headaches or nausea
• Localized tumor pain (due to inflammation)

In rare cases, stronger symptoms may occur. Our patients receive treatment in a hospital-grade facility with emergency capabilities, and our team is fully prepared to manage complications if they arise.

Important notes:

• Side effects often peak 24–72 hours after Dendritic Cell administration.
• They may linger for weeks or months as your immune system continues fighting.
• Our treatment protocol includes careful monitoring and preventive measures to manage potential complications.

Pseudoprogression occurs when tumors appear to grow or light up on scans — not because they’re spreading, but because the immune system is attacking them. This immune infiltration can cause:

• Swelling or inflammation on imaging
• Spikes in tumor markers or ctDNA
• New lesions appearing as immune clusters grow

Pseudoprogression is a common occurrence during immunotherapy treatment, and may be observed for several months as part of the immune response. It’s a good sign, but it can look like worsening disease — which is why ongoing monitoring with our team is crucial.

Pseudoprogression is more likely if:

• Your symptoms are improving despite “worse” scans
• Only one marker is rising while others improve
• Steroids reduce symptoms (suggesting inflammation, not tumor growth)

We help you interpret these signals correctly — because mistaking immune activity for cancer progression can lead to premature decisions.

While our treatment is currently offered through COFEPRIS approval in Mexico, clinical trials evaluating similar technologies are ongoing in the U.S. Our Cancun location enables us to provide this innovative therapy under established regulatory frameworks while maintaining the highest standards of care.

Here’s why we chose Cancun:
• We operate from a certified ISO-7 cleanroom lab with strict regulatory oversight.
• Our medical team includes experienced oncologists and interventional radiologists, many trained in both the U.S. and Mexico.
• Care is delivered within a legal compassionate-use framework approved by COFEPRIS.
• We partner with accredited hospitals like Amerimed, fully equipped for cancer care.
• Treatment here is significantly less expensive than it would be in the U.S.
• Patients often combine treatment with rest and recovery in a peaceful, vacation-like setting.

Cancun checks all the boxes: scientific integrity, clinical safety, legal approval, and patient experience.

Once you’re ready to begin, you’ll go through the following steps:

• Select your preferred start date in Cancun
• Receive the following via DocuSign:
o Informed Consent
o Instructions for Infectious Disease Testing
o Payment Instructions / Invoice
• Ensure your passport is valid
• Get introduced to your personal CARE Team, who will guide your ongoing support
• Coordinate with our Cancun-based concierge to plan travel and logistics
• Review and approve your treatment schedule
• Complete payment before arrival, so we can prepare for your care

With respect to biosafety parameters of our ISO-7 certified laboratory in Cancun, we are prohibited from working with any tissue or blood positive for one of 8 infections. We cannot process and utilize your tumor material until we have received valid documentation that you are negative for 8 infections. Those infections include:

-HIV-1/2 antigen and antibodies 4th Gen (CPT: 87389)
-Hepatitis B antigen (CPT: 87340)
-Hepatitis C antibody (CPT: 86803)
-Treponema pallidum (CPT: 86592)
-Trypanosoma cruzi (CPT: 86753)
-Toxoplasmosis (Toxoplasma Antibody IgM (CPT:86778))
-Epsetin-Barr virus (EBV VCA IgM test (CPT: 86665))
-Cytomegalovirus (CMV IgM tests (CPT: 86645))

Importantly, if positive for Toxoplasmosis, EBV, or CMV, we can work with your tissue if obtained after those infections have resolved.

If there is a positive test here (indicating immunological activity) and you believe it may be a false positive, please consider running the more specific, confirmatory tests. That can include:

-HIV RNA (CPT: 87536)
-Hepatitis B Viral DNA (CPT: 87617)
-Hepatitis C Viral RNA (CPT: 87522)
-Cytomegalovirus DNA (CPT: 87496)
-Toxoplasma gondii DNA (CPT: 87798)
-Treponema pallidum Antibodies (CPT: 86780)
-Epstein-Barr Viral DNA (CPT: 87799)

If these tests are successfully completed within 30 days of the procedure (before or after) and negative, then we are permitted to handle your tissue. As a note, you may want to consider running the tests a couple of weeks before the procedure to have peace of mind that no infection will be in the way. If ultimately we are unable to use the kit because of a positive test result, you would receive a 50% refund.

Any CLIA laboratory or certified doctor can put these tests in for you. If you need assistance, you will have the opportunity in the Immunocine Preserve portal to request that we facilitate the test orders for you. We are partnered with Ulta Lab tests, and they will provide required scripts. If through us, it will cost $395.

It is very unlikely. We are only able to use tissue that has a documented blood draw within 30 days of tissue resection that shows negative results for the infections listed elsewhere in this document. Given that is unlikely, it is unlikely we would be allowed to use this tissue.

Not usable if:
-Stored in formalin (standard pathology method)
-Left out at room temperature
-Preserved only for routine genetic testing

Possibly usable if:
-Immediately cryopreserved (frozen under precise lab-grade conditions)
-Quantity and quality are suficient after in-lab testing

We’re happy to evaluate any stored tissue, but will need to review viability to ensure success.

Yes — this can be an ideal opportunity to preserve a viable tumor sample if it’s handled correctly. Please contact us as soon as possible so we can provide a Preservation Kit and share the necessary handling instructions.

Note: We’re happy to coordinate with your surgical team if they would like to collaborate, but we are not able to manage the logistics directly with hospitals or surgeons.

Cost: $6,000 (non-refundable, partially credited toward future treatment) Proper Preservation Requirements:

• Use of RNAlater or flash-freezing methods
• Immediate refrigeration (2–8°C)
• Minimum 250mg of tissue
• Priority on RNA preservation (e.g., 80/20 split with pathology)
• Avoid any exposure to formalin

Other Requirements:

• Infectious disease tests must be completed within ±3 weeks of collection
• Pathology confirmation of cancer is required
• Your surgical team must complete documentation to approve specimen release

More detailed instructions will be included with the kit and/or provided by email in advance.

Please visit ImmunocinePreserve.com to register today.

Maybe — it depends on what you’re considering.

While some therapies, supplements, or alternative treatments may be compatible with our treatment protocol, others could potentially interfere with or diminish treatment effectiveness. Patients must disclose all current and planned treatments to our CARE team for assessment and receive written approval before combining any additional therapies with Immunocine treatment.

As for standard oncology treatments:

• In some cases, we may advise completing them before starting with us
• In other cases, we may recommend pausing them during Immunocine treatment
• This will be discussed during your Approval Call

Importantly, Immunocine does not close doors to future treatments — chemo, radiation, clinical trials, or alternative protocols remain available if needed.

Unfortunately, cancer care can be very expensive, even when covered by insurance. A lot of patients do not realize that they will ultimately spend on average $140,000-$220,000 for the first year when all is said and done with care throughout the process^1,2,3,4. This is often accomplished by ongoing “never-ending” bills, surge prices when extra consultations and such are requested, battles (and valuable time lost) with insurance companies, and often a continued lack of communication and time with the doctors and scientists involved in the patient’s case. Indeed, there may not be ‘upfront, sticker shock’ within this mainstream model, but the invoices do pile up.

To try and be transparent and reduce stress on the patient, Immunocine operates via a one-time fee model which covers all that goes into production and treatment, with no “ongoing bills,” “black holes,” or dearth of communication that often frustrate patients and their families.

The treatment program fee is $120,000 USD, covering the core medical, scientific and logistical components of your personalized therapy program.

Below is a general overview of what is covered; but a more in-depth look at the relative costs and values can be found here.

This covers:

• All doctors, specialists, lab work, scans, and procedures
• Collection and manufacturing of your personalized Dendritic Cell therapy
• Scientific personnel, reagents, and quality control certifications
• Image-guided administration of activated Dendritic Cells near draining lymph nodes
• Storage of extra Dendritic Cells for potential future boosts
• Immune-enhancing agents (e.g. IFN-α, CpG) when applicable
• Continual and responsive interaction and data review with our medical and advisory team
• A private driver for airport and medical transport
• Full concierge coordination
• Deep dive, patient-specific immunological analytics

There are no hidden fees or a la carte upsells. Once accepted into the program, this is your price.

Not included:

• Airfare or lodging (our team will help arrange both and offer preferred hotel rates)
• Cost of future Dendritic Cell “boosts” ($9,000 per boost, if pursued later)
• Emergency interventions not directly related to the treatment protocol

We also offer a transparent refund policy, which can be further explained below.

1) https://progressreport.cancer.gov/after/economic_burden
2) https://pubmed.ncbi.nlm.nih.gov/39367130/
3) https://www.managedhealthcareexecutive.com/view/the-cost-of-new-cancer-drugs-is-increasing
4) https://www.psu.edu/news/research/story/cancer-costs-us-more-156-billion-drugs-leading-expense

Yes. We offer a tiered refund policy that reflects our commitment to fairness and transparency.

Full Refund:

• 100% if canceled more than 3 weeks before your start date
• 95% if canceled within 3 weeks and no medical procedures have begun

Partial Refunds (Post Arrival):

Stage of Treatment	Refund Amount
Before scans/tests/biopsy	90%
After baseline scans	80%
After biopsy	70%
After apheresis	50%
After first cell injection	0%

Potential Reasons for Treatment Suspension include:

• Insufficient biopsy or cell sample
• Sudden illness or emergency
• New medical complications
• Immunocine team decision to pause treatment for safety

Due to the complexity and cost of manufacturing the personalized treatment, no refunds can be provided once treatment has commenced with the first injection.

To ensure optimal treatment efficacy and operational efficiency, patients are required to adhere to their scheduled appointments. Multiple missed appointments or consistent delays may necessitate treatment cancellation without refund, as such disruptions impact both treatment effectiveness and facility operations.

While Immunocine does not directly offer financing, we can connect you with third-party providers who specialize in medical financing:

LightStream Medical Financing:
• Fixed-rate loans with no collateral required
• Terms of 3–7 years
• Fast approval process, often within 5 days

Life Credit:
• May allow you to borrow against your life insurance policy
• We recommend reviewing terms directly with Life Credit, as Immunocine does not endorse or manage these agreements

Let us know if you’re interested in learning more.

In most cases, insurance does not cover this treatment upfront — so we recommend you plan to pay out-of-pocket.

However, we’ve had patients successfully recover significant funds through insurance reimbursement after treatment.

We now partner with a third-party reimbursement group that:

• Specializes in medical tourism
• Works on a contingency basis (no upfront cost)
• Only takes a fee from recovered funds

This team can assist with submitting your documentation post-treatment. While insurance coverage cannot be guaranteed and should not be assumed, some patients have successfully obtained reimbursement. Immunocine makes no representations or warranties regarding insurance coverage

Once you’re approved, our Cancun concierge team will contact you directly to guide every step of your travel planning.

We’ll help you:
• Choose from vetted hotel options (with preferred rates)
• Coordinate airport pick-up and medical transport
• Finalize your treatment and lab schedule in advance

We want you focused on healing — not logistics.

Cancer isn’t a single enemy — it’s a constantly evolving, immune-suppressing, metabolically aggressive force that uses your own biology against you. Here’s why it’s so difficult to treat:

• It’s constantly changing. Within a single tumor, there may be hundreds of variations of cancer cells, making it hard for treatments to stay effective.

• It suppresses the immune system. Tumors release chemicals and present surface markers (like PD-L1) that actively shut down immune responses.

• It grows fast. Some cancers grow faster than treatments can catch up.

• It hijacks your metabolism. Cancer cells consume massive energy and flood their surroundings with waste that weakens immune cells.

• It’s genetically unstable. Cancer adapts rapidly, developing resistance to drugs.

• It hides in hard-to-reach places. Location can make treatment riskier or less effective.

How we’re different:

Our treatment educates your immune system using the full mRNA (the underlying blueprints) and protein library (the structural representation) of your cancer — not just a single marker. Even as cancer changes, your immune system has been taught to recognize multiple features of the threat. We don’t try to outrun cancer — we give your body the tools to find it, adapt to it, and destroy it.

Immunotherapy is a category of cancer treatments that harness your immune system to fight cancer — instead of attacking cancer cells directly with drugs or radiation.

Think of your immune system as a military force. Most immunotherapies either remove the brakes, give it new weapons, or send it into battle. Immunocine trains it — teaching your immune system who the enemy is and how to fight it.

Here’s how some current FDA-approved immunotherapies work:

Checkpoint Inhibitors (e.g. Keytruda, Opdivo):
• Remove the immune system’s “brakes”
• Work only if your immune system already recognizes the cancer • Effective in 15–25% of patients
• Immunocine Advantage: We teach your immune system to recognize cancer first — potentially making these therapies effective later

CAR-T Cell Therapy:
• Engineers your T-cells in a lab to target one cancer protein
• Costly ($400k+), often ineffective for solid tumors, high side effect risk
• Immunocine Advantage: We target your entire cancer, not just one marker — with less risk of autoimmune sequelae

Monoclonal Antibodies (e.g. Herceptin):
• Lab-made proteins that bind to specific cancer proteins
• Cancer often mutates around them
• Immunocine Advantage: We train the immune system to recognize multiple targets, not just one

Our Dendritic Cell Approach:
• Personalized to your specific cancer
• Uses your entire cancer profile (mRNA + protein)
• Works regardless of biomarkers like PD-L1
• Fewer side effects, biologically aligned with your immune system
• Applicable to most solid tumors
• Less expensive and more accessible than CAR-T

Key takeaway: Most immunotherapies enhance a response. We create one. We don’t just take the brakes off — we give your immune system a map, a mission, and the training to succeed.

Traditional cancer drugs target a single pathway or protein. Cancer mutates around them — like rerouting traffic around a blocked road. Our approach is different. We don’t target just one feature. We train your immune system to recognize your entire cancer fingerprint, making it much harder for the cancer to hide or adapt.

Here’s why resistance is less likely:

• Multi-target recognition: We educate your immune system on dozens or even hundreds of unique cancer markers
• Immune memory: Unlike drugs, your immune system remembers what to look for
• Broad pressure: We don’t give cancer a single threat to escape — we surround it
• Natural surveillance: We’re restoring a system evolved over millions of years to protect you
• Dynamic adaptation: Your immune system can evolve alongside the cancer
• Metabolic targeting: We teach your immune system to recognize how cancer behaves, not just what it looks like

Cancer can mutate around a drug. It can’t easily escape an immune system that understands its full identity.

Early clinical observations have shown promising results, though long-term data collection is ongoing.

• In our experience, we have observed patients who have remained cancer-free for extended periods following treatment, including one case exceeding 7 years.
• Several others are approaching 5 years with no recurrence
• These aren’t just survival stats — these are full, active lives being lived

Why we believe it lasts:
• Our treatment generates CD8+CD161+ memory T cells — long-lasting immune cells with:
o Superior killing power
o Tissue-homing ability
o Resistance to exhaustion
o Self-renewal capacity

Think of it like installing a permanent security system in your body — one that never clocks out.

Additional safeguards:
• Booster doses can be stored and administered if needed
• Repeat treatment is possible — your immune system can’t develop resistance to itself
• Our approach creates durable immune memory — just like childhood vaccines

While individual results may vary, our treatment approach is based on established immunological principles that support the potential for long-term immune response against cancer cells.